Puma Biotechnology Inc (PBYI) : Lamond Capital Partners has sold out all of its stake in Puma Biotechnology Inc during the most recent quarter, according to the disclosure filed by the company on Jul 19, 2016 with the SEC. The investment management company has sold out 220,780 shares of Puma Biotechnology Inc which is valued at $7,301,195.
Other Hedge Funds, Including , Fox Run Management L.l.c. sold out all of its stake in PBYI during the most recent quarter. The investment firm sold 13,100 shares of PBYI which is valued $433,217.Simplex Trading reduced its stake in PBYI by selling 4,410 shares or 35.12% in the most recent quarter. The Hedge Fund company now holds 8,148 shares of PBYI which is valued at $269,454. Puma Biotechnology Inc makes up approx 0.03% of Simplex Trading’s portfolio. Nisa Investment Advisors sold out all of its stake in PBYI during the most recent quarter. The investment firm sold 300 shares of PBYI which is valued $9,915.Cutler Group Lp reduced its stake in PBYI by selling 12,027 shares or 57.29% in the most recent quarter. The Hedge Fund company now holds 8,966 shares of PBYI which is valued at $293,816. Puma Biotechnology Inc makes up approx 0.02% of Cutler Group Lp’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in PBYI in the latest quarter, The investment management firm added 980 additional shares and now holds a total of 34,025 shares of Puma Biotechnology Inc which is valued at $1,114,999. Puma Biotechnology Inc makes up approx 0.21% of Franklin Street Advisors Inc Nc’s portfolio.
Puma Biotechnology Inc opened for trading at $31.3 and hit $33.09 on the upside on Wednesday, eventually ending the session at $33.07, with a gain of 6.13% or 1.91 points. The heightened volatility saw the trading volume jump to 4,71,413 shares. Company has a market cap of $1,075 M.
Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.